Dark

Check out our API

BPMC
Blueprint Medicines Corporation
stock NASDAQ

Inactive

Jul 17, 2025

129.46USD+0.139%(+0.18)2,980,995

Pre-market

0.00USD-100.000%(-129.28)0

After-hours

0.00USD0.000%(0.00)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 28, 2022

08:21AM EST Blueprint Medicines Reports Positive CHMP Opinion To RTTNews

08:10AM EST Blueprint Medicines' AYVAKYT Receives Positive CHMP Opinion For Treatment Of Advanced Systemic Mastocytosis RTTNews

08:06AM EST Blueprint Medicines' AYVAKYT Receives Positive CHMP Opinion For Treatment Of Adults With Advanced Systemic Mastocytosis Benzinga

08:01AM EST Blueprint Medicines' AYVAKYT(r) (avapritinib) Receives Positive CHMP Opinion PR Newswire

Jan 25, 2022

01:03PM EST Analyst Ratings For Blueprint Medicines Benzinga

10:03AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 25, 2022 Benzinga

09:23AM EST 10 Biggest Price Target Changes For Tuesday Benzinga

05:00AM EST Stifel Upgrades Blueprint Medicines to Buy, Lowers Price Target to $95 Benzinga

Jan 20, 2022

08:10AM EST Blueprint Medicines Promotes Philina Lee To Chief Commercial Officer RTTNews

08:01AM EST Blueprint Medicines Elevates Two Talented Leaders to its Executive Team PR Newswire

Jan 12, 2022

08:05AM EST SVB Leerink Maintains Outperform on Blueprint Medicines, Lowers Price Target to $120 Benzinga

Jan 10, 2022

08:20AM EST Blueprint Medicines Reports 2021 Preliminary Global Net Product Revenue For AYVAKIT Of $52.9 MLN, Increase Of 150% RTTNews

08:12AM EST Blueprint Medicines Sees FY21 Global Net Product Sales For AYVAKIT ~$52.9M; Sees FY21 Total Sales At Higher End Of $170M-$180M Guidance Range vs $173.2M Estimate Benzinga

08:01AM EST Blueprint Medicines Provides 2022 Portfolio Goals Targeting Expanded Precision PR Newswire

Jan 6, 2022

04:01PM EST Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule PR Newswire

Jan 5, 2022

08:24AM EST Blueprint Medicines Appoints Kate Haviland To Succeed Jeff Albers As CEO, Effective April 4 RTTNews

08:01AM EST Blueprint Medicines Announces CEO and Leadership Transition Plan PR Newswire

Dec 30, 2021

08:59AM EST Blueprint Medicines Completes Acquisition Of Lengo Therapeutics RTTNews

Dec 9, 2021

04:15PM EST Blueprint Medicines Appoints Daniella Beckman To Its Board Of Directors RTTNews

Dec 7, 2021

04:01PM EST Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule PR Newswire

Dec 6, 2021

04:06PM EST Nature Medicine Publishes Results From Two Registration Studies Of AYVAKIT Showing Sustained Benefits In Patients With Advanced Systemic Mastocytosis Benzinga

04:01PM EST (avapritinib) Showing Sustained Benefits in Patients with Advanced Systemic Mastocytosis PR Newswire

Nov 29, 2021

07:41AM EST Blueprint Medicines Corporation (BPMC), said on Monday that it inked a definitive agreement to acquire Lengo Therapeutics, a privately held precision oncology firm, for $250 million in cash and up to $215 million in additional potential payments. RTTNews

07:10AM EST Blueprint Medicines To Buy Lengo Therapeutics RTTNews

07:01AM EST Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with PR Newswire

Nov 10, 2021

05:05AM EST Raymond James Maintains Strong Buy on Blueprint Medicines, Raises Price Target to $133 Benzinga

Nov 9, 2021

11:57AM EST Zai Lab Inks Back To Back Licensing Agreements For Cancer And Psychiatric Candidates Benzinga

11:41AM EST Zai Lab And Blueprint Medicines Announce Strategic Collaboration And License Agreement For BLU-945 And BLU-701 In Greater China; Blueprint Medicines To Receive $25M Upfront Payment, Up To $590M In Potential Future Milestone Payments Benzinga

08:11AM EST Blueprint Medicines, Zai Lab Unveil Collaboration And License Deal For BLU-945 And BLU-701 In Greater China RTTNews

08:03AM EST Blueprint Medicines and Zai Lab Announce Strategic Collaboration and License PR Newswire

08:00AM EST -- Zai Lab obtains exclusive rights to develop and commercialize BLU-945 and BLU-701 in Greater China -- GlobeNewswire Inc

Nov 5, 2021

04:01PM EDT Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule PR Newswire

Oct 29, 2021

09:41AM EDT Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $111 Benzinga

Oct 28, 2021

08:26AM EDT The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug Benzinga

07:37AM EDT Blueprint Medicines Raises FY21 Sales Guidance To $170M-$180M vs $148.4M Estimate Benzinga

07:35AM EDT Blueprint Medicines Q3 EPS $(2.00) Misses $(1.63) Estimate, Sales $24.20M Down From $745.12M YoY Benzinga

07:27AM EDT Blueprint Medicines Q3 Loss/shr $2.00 Vs. EPS $11.16 Last Year RTTNews

07:02AM EDT Blueprint Medicines Reports Third Quarter 2021 Financial Results PR Newswire

04:08AM EDT Earnings Scheduled For October 28, 2021 Benzinga

Oct 24, 2021

11:45AM EDT The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More Benzinga

Oct 21, 2021

08:02AM EDT Blueprint Medicines to Report Third Quarter 2021 Financial Results on Thursday, PR Newswire

Oct 5, 2021

04:01PM EDT Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule PR Newswire

Sep 17, 2021

07:34AM EDT Roche Announces Positive CHMP Opinion For Gavreto In RET RTTNews

Sep 3, 2021

04:01PM EDT Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule PR Newswire

Sep 2, 2021

08:01AM EDT Blueprint Medicines to Present at Morgan Stanley 19th Annual Global Healthcare PR Newswire

Aug 4, 2021

04:01PM EDT Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule PR Newswire

Jul 30, 2021

11:51AM EDT Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Lowers Price Target to $96 Benzinga

Jul 29, 2021

08:18AM EDT The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs Benzinga

07:46AM EDT Blueprint Medicines Q2 EPS $(1.86), Inline, Sales $27.30M Beat $19.01M Estimate Benzinga

07:43AM EDT Blueprint Medicines: Q2 Earnings Insights Benzinga

07:27AM EDT Blueprint Medicines Q2 Loss/shr $1.86 Vs. Loss/shr $2.28 Last Year RTTNews

07:01AM EDT Blueprint Medicines Reports Second Quarter 2021 Financial Results PR Newswire

04:23AM EDT Earnings Scheduled For July 29, 2021 Benzinga

Jul 28, 2021

08:07AM EDT MD Anderson And Blueprint Medicines Collaborate To Accelerate BLU-222 Development RTTNews

08:02AM EDT Blueprint Medicines Reports 3-Year Strategic Collab With University Of Texas MD Anderson Cancer Center To Accelerate Development Of BLU-222 For Cyclin-Dependent Kinase 2 Benzinga

08:01AM EDT MD Anderson and Blueprint Medicines Announce Strategic Collaboration to PR Newswire

Jul 25, 2021

10:05AM EDT The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More Benzinga

Jul 22, 2021

08:01AM EDT Blueprint Medicines to Report Second Quarter 2021 Financial Results on PR Newswire

Jul 7, 2021

04:01PM EDT Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule PR Newswire

Jun 17, 2021

10:57AM EDT Analyst Ratings for Blueprint Medicines Benzinga

09:25AM EDT Wedbush Maintains Outperform on Blueprint Medicines, Lowers Price Target to $130 Benzinga

09:22AM EDT SVB Leerink Maintains Outperform on Blueprint Medicines, Raises Price Target to $137 Benzinga

09:21AM EDT Baird Maintains Outperform on Blueprint Medicines, Raises Price Target to $123 Benzinga

Jun 16, 2021

03:59PM EDT Blueprint Medicines Wins FDA Approval For AYVAKIT Efficacy For Adults With Advanced Systemic Mastocytosis Benzinga

03:50PM EDT FDA Approves Blueprint Medicines' AYVAKIT(tm) (avapritinib) for the Treatment PR Newswire

03:40PM EDT Blueprint Medicines Wins FDA Approval For AYVAKIT Efficacy Benzinga

08:20AM EDT The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO Benzinga

Jun 4, 2021

04:01PM EDT Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule PR Newswire

Jun 2, 2021

10:38AM EDT Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates Benzinga

May 25, 2021

08:01AM EDT Blueprint Medicines to Present at Upcoming Investor Conferences PR Newswire

May 19, 2021

05:25PM EDT Pharma/Biotech Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Jun. 4-8, 2021 Benzinga

05:01PM EDT Highlighting Durable Clinical Activity in Patients with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer and Other Advanced Solid Tumors PR Newswire

May 17, 2021

08:13AM EDT Blueprint Medicines Appoints Percy Carter As Chief Scientific Officer, Effective May 19 RTTNews

08:01AM EDT Blueprint Medicines Appoints Percy Carter, MBA, Ph.D., as Chief Scientific PR Newswire

May 5, 2021

04:02PM EDT Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule PR Newswire

Apr 30, 2021

07:49AM EDT Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Lowers Price Target to $101 Benzinga

Apr 29, 2021

08:35AM EDT Blueprint Medicines Q1 Net Loss $99.7 Mln Or $1.72/shr Vs Net Loss Of $111.0 Mln Or $2.11/shr Prior Year RTTNews

08:15AM EDT The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx Benzinga

08:01AM EDT Recap: Blueprint Medicines Q1 Earnings Benzinga

07:21AM EDT Blueprint Medicines Q1 EPS $(1.72) Beats $(1.86) Estimate, Sales $21.58M Beat $17.25M Estimate Benzinga

07:02AM EDT Blueprint Medicines Reports First Quarter 2021 Financial Results PR Newswire

04:10AM EDT Earnings Scheduled For April 29, 2021 Benzinga

Apr 24, 2021

09:24AM EDT The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx Benzinga

Apr 22, 2021

08:02AM EDT Blueprint Medicines to Report First Quarter 2021 Financial Results on Thursday, PR Newswire

Apr 13, 2021

10:55AM EDT Wedbush Maintains Outperform on Blueprint Medicines, Raises Price Target to $136 Benzinga

Apr 12, 2021

10:13AM EDT Blueprint Medicines Saturday Morning Announced Presentation Of Preclinical Data For Its Precision Therapy Research Pipeline At American Association For Cancer Research Apr. 11, 2021 Benzinga

Apr 11, 2021

02:00PM EDT Blueprint Medicines Data Highlight Clinical Leadership in Systemic Mastocytosis PR Newswire

Apr 10, 2021

09:19AM EDT The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight Benzinga

08:31AM EDT Blueprint Medicines Presents Preclinical Data Highlighting Broad Precision PR Newswire

Apr 7, 2021

04:01PM EDT Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule PR Newswire

Apr 5, 2021

08:01AM EDT Blueprint Medicines to Host Virtual Investor Event and Webcast to Review New PR Newswire

Mar 31, 2021

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2021 Benzinga

07:13AM EDT Credit Suisse Initiates Coverage On Blueprint Medicines with Neutral Rating, Announces Price Target of $100 Benzinga

Mar 10, 2021

04:31PM EST Blueprint Medicines to Showcase Scientific Leadership in Precision Oncology and PR Newswire

Mar 5, 2021

04:01PM EST Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule PR Newswire

Mar 3, 2021

08:36AM EST Blueprint : EMA Validates Type II Variation MAA For AYVAKYT For The Treatment Of Advanced Systemic Mastocytosis RTTNews

08:04AM EST Blueprint Medicines Reports European Medicines Agency Validation Of Co.'s Type 2 Variation Marketing Authorization Application For AYVAKYT For Treatment Of Advanced Systemic Mastocytosis Benzinga

08:01AM EST Authorization Application for AYVAKYT(r) (avapritinib) for the Treatment of Advanced Systemic Mastocytosis PR Newswire

Feb 18, 2021

09:47AM EST Barclays Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $95 Benzinga

08:14AM EST The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout Benzinga

08:04AM EST Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Lowers Price Target to $105 Benzinga

Feb 17, 2021

07:36AM EST Recap: Blueprint Medicines Q4 Earnings Benzinga

07:14AM EST Blueprint Medicines Q4 EPS $(1.53) Beats $(1.62) Estimate, Sales $34.11M Beat $29.24M Estimate Benzinga

07:10AM EST Blueprint Medicines Q4 Net Loss $85.7 Mln Or $1.53/shr Vs. Net Loss $66.3 Mln Or $1.35/shr Last Year RTTNews

07:10AM EST Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results PR Newswire

04:34AM EST Earnings Scheduled For February 17, 2021 Benzinga

Feb 10, 2021

08:01AM EST Blueprint Medicines to Report Fourth Quarter and Full Year 2020 Financial PR Newswire

Feb 5, 2021

04:01PM EST Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule PR Newswire

Jan 12, 2021

07:09AM EST SVB Leerink Maintains Outperform on Blueprint Medicines, Raises Price Target to $127 Benzinga

Jan 11, 2021

08:26AM EST Blueprint Medicines And Roche Agreed To Modify Certain Time Periods Related To Roche's Option Rights For One Of Collaboration Programs Benzinga

08:05AM EST Blueprint Medicines Announces R&D Leadership Transitions PR Newswire

08:01AM EST Blueprint Medicines Reports Portfolio Milestones and Outlines 2021 Roadmap for PR Newswire

Jan 5, 2021

04:01PM EST Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule PR Newswire

Dec 23, 2020

08:31AM EST The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut Benzinga

Dec 17, 2020

08:03AM EST Blueprint Medicines Submits Supplemental New Drug Application To FDA For AYVAKIT For the Treatment Of Advanced Systemic Mastocytosis Benzinga

08:02AM EST AYVAKIT(tm) (avapritinib) for the Treatment of Advanced Systemic Mastocytosis PR Newswire

Dec 15, 2020

07:52AM EST The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding Benzinga

Dec 11, 2020

08:11AM EST The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street Benzinga

Dec 7, 2020

08:09AM EST Blueprint Medicines Highlights Data Presented At 62nd ASH Annual Meeting Benzinga

08:01AM EST Blueprint Medicines Data Presented at 62nd ASH Annual Meeting and Exposition PR Newswire

Dec 6, 2020

08:41AM EST Week Ahead In Biotech: FDA To Decide On Emergency Use Of Pfizer's COVID Vaccine, Hematology Conference Presentations Pick Up Pace Benzinga

Dec 4, 2020

04:01PM EST Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule PR Newswire

Dec 3, 2020

09:56AM EST Benzinga's Top Upgrades, Downgrades For December 3, 2020 Benzinga

Dec 2, 2020

07:35AM EST The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod Benzinga

Dec 1, 2020

03:15PM EST Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer PR Newswire

02:37PM EST FDA Approves Blueprint Medicine's Gavreto Capsules For Oral Use Benzinga

08:08AM EST The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit Benzinga

Nov 23, 2020

08:01AM EST Advance Patient Care in Systemic Mastocytosis at 62nd ASH Annual Meeting and Exposition PR Newswire

Nov 3, 2020

04:01PM EST Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule PR Newswire

Nov 2, 2020

09:56AM EST Benzinga's Top Upgrades, Downgrades For November 2, 2020 Benzinga

06:19AM EST Jefferies Downgrades Blueprint Medicines to Hold, Announces $96 Price Target Benzinga

Oct 30, 2020

10:06AM EDT Benzinga's Top Upgrades, Downgrades For October 30, 2020 Benzinga

08:09AM EDT The Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinson's Study, 2 Biotechs Make Wall Street Debuts Benzinga

06:16AM EDT Morgan Stanley Downgrades Blueprint Medicines to Equal-Weight Benzinga

Oct 29, 2020

07:45AM EDT Blueprint Medicines Q3 Net Income $634.0 Mln Or $11.16/shr Vs. Net Loss $94.3 Mln Or $1.93/shr Last Year RTTNews

07:44AM EDT Blueprint Medicines Q3 EPS $11.16 Beats $7.72 Estimate, Sales $745.12M Beat $631.57M Estimate Benzinga

07:38AM EDT Blueprint Medicines: Q3 Earnings Insights Benzinga

07:30AM EDT The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal Benzinga

07:01AM EDT Blueprint Medicines Reports Third Quarter 2020 Financial Results PR Newswire

04:08AM EDT Earnings Scheduled For October 29, 2020 Benzinga

Oct 27, 2020

08:25AM EDT The Daily Biotech Pulse: Catabasis Halts Duchenne Muscular Dystrophy Study, Lilly's COVID-19 Trial Disappointment, Merck, Pfizer Earnings Benzinga

Oct 22, 2020

08:02AM EDT Blueprint Medicines to Report Third Quarter 2020 Financial Results on Thursday, PR Newswire

Oct 21, 2020

08:04AM EDT The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings Benzinga

Oct 20, 2020

08:17AM EDT The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger Benzinga

Oct 16, 2020

08:16AM EDT 10 Biggest Price Target Changes For Friday Benzinga

07:27AM EDT Raymond James Maintains Strong Buy on Blueprint Medicines, Raises Price Target to $122 Benzinga

Oct 13, 2020

08:32AM EDT Morgan Stanley Maintains Overweight on Blueprint Medicines, Raises Price Target to $100 Benzinga

Oct 2, 2020

04:01PM EDT Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule PR Newswire

Sep 25, 2020

11:48AM EDT Blueprint Medicines Reports European Commission Approval Of AYVAKYT For Treatment Of Adults With Unresectable, Metastatic Platelet-Derived growth Factor Receptor Alpha Mutant Gastrointestinal Stromal Tumors Benzinga

11:47AM EDT (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors PR Newswire

Sep 22, 2020

10:11AM EDT Shares of drugmaker Blueprint Medicines Corporation (BPMC) are climbing more than 10% Tuesday morning after reporting positive topline results from phase I Explorer study and phase II Pathfinder study of Ayvakit (avapritinib) in patients with advanced systemic mastocytosis. RTTNews

07:05AM EDT Blueprint Medicines Announces Positive Top-line Results From EXPLORER And PATHFINDER Trials Of AYVAKIT RTTNews

07:03AM EDT Blueprint Medicines Announces Top-line Results From EXPLORER And PATHFINDER Trials Of AYVAKIT In Patients With Advanced Systemic Mastocytosis Benzinga

07:01AM EDT PATHFINDER Trials of AYVAKIT(tm) (avapritinib) in Patients with Advanced Systemic Mastocytosis PR Newswire

Sep 20, 2020

11:52AM EDT Blueprint Medicines Reports ARROW Trial Data At ESMO Virtual Congress 2020 RTTNews

08:32AM EDT Blueprint Medicines Presents ARROW Trial Data at ESMO 2020 Demonstrating Durable Clinical Benefits of GAVRETO in Patients with Advanced RET-Mutant Medullary Thyroid Cancer Benzinga

08:25AM EDT Demonstrating Durable Clinical Benefits of GAVRETO(tm) (Pralsetinib) in Patients with Advanced RET-Mutant Medullary Thyroid Cancer PR Newswire

Sep 17, 2020

08:01AM EDT Robust Anti-Tumor Activity in Treatment-Resistant EGFR-Mutated Lung Cancer at ESMO Virtual Congress 2020 PR Newswire

Sep 9, 2020

04:01PM EDT Blueprint Medicines to Present at 18th Annual Morgan Stanley Global Healthcare PR Newswire

Sep 4, 2020

07:00PM EDT Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer PR Newswire

08:02AM EDT Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) RTTNews

08:01AM EDT Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule PR Newswire

Sep 1, 2020

08:03AM EDT Blueprint Medicines Appoints Fouad Namouni As President, Research & Development RTTNews

08:01AM EDT Blueprint Medicines Strengthens Leadership with Appointment of Fouad Namouni, PR Newswire

Aug 4, 2020

08:01AM EDT Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule PR Newswire

Jul 30, 2020

07:46AM EDT Blueprint Medicines Q2 EPS $(2.28) Misses $(2.14) Estimate, Sales $8.34M Beat $6.60M Estimate Benzinga

07:28AM EDT Recap: Blueprint Medicines Q2 Earnings Benzinga

07:24AM EDT Blueprint Medicines Q2 Net Loss $123.5 Mln Or $2.28/shr Vs. Net Loss $99.7 Mln Or $2.04/shr Last Year RTTNews

07:01AM EDT Blueprint Medicines Reports Second Quarter 2020 Financial Results PR Newswire

04:06AM EDT Earnings Scheduled For July 30, 2020 Benzinga

Jul 27, 2020

08:18AM EDT SVB Leerink Maintains Outperform on Blueprint Medicines, Raises Price Target to $107 Benzinga

Jul 24, 2020

08:36AM EDT Blueprint Medicines Reports Positive CHMP Opinion For Avapritinib For Treatment Of Adults with Unresectable Or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors Benzinga

08:34AM EDT Blueprint Medicines Receives Positive CHMP Opinion For Avapritinib RTTNews

08:31AM EDT Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors PR Newswire

Jul 23, 2020

08:01AM EDT Blueprint Medicines to Report Second Quarter 2020 Financial Results on PR Newswire

Jul 15, 2020

10:01AM EDT Morgan Stanley Maintains Overweight on Blueprint Medicines, Raises Price Target to $92 Benzinga

09:56AM EDT Blueprint Medicines shares are trading higher after HC Wainwright maintained a Buy rating on the stock and raised its price target from $66 to $110. The company on Tuesday announced a collaboration with Roche. Benzinga

08:12AM EDT 10 Biggest Price Target Changes For Wednesday Benzinga

07:16AM EDT SVB Leerink Maintains Outperform on Blueprint Medicines, Raises Price Target to $106 Benzinga

06:25AM EDT HC Wainwright & Co. Maintains Buy on Blueprint Medicines, Raises Price Target to $110 Benzinga

Jul 14, 2020

05:42AM EDT Blueprint Medicines Announces Global Collaboration with Roche to Develop and Commercialize Pralsetinib for Patients with RET-Altered Cancers; Blueprint to Receive $775M in Upfront Payments Benzinga

05:26AM EDT Blueprint Medicines Announces Global Collaboration with Roche to Develop and Commercialize Pralsetinib for Patients with RET-Altered Cancers Benzinga

01:08AM EDT Blueprint Medicines Collaborates With Roche To Develop &Commercialize Pralsetinib For Patients With RET-Altered Cancers RTTNews

01:05AM EDT Roche, Blueprint Medicines Announce Signing Of Licensing And Collaboration Agreement RTTNews

01:00AM EDT Blueprint Medicines Announces Global Collaboration with Roche to Develop and PR Newswire

Share